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Introduction 
The Journal of Clinical Epidemiology is the main forum for discussions on prospectively 
matching pragmatic or explanatory intent with the design of single randomized controlled 
trial (RCTs). With this paper by Dal-Ré et al1 it has also become a forum for discussing the 
PRECIS-2 tool2  for retrospectively assessing multiple RCTs within reviews. PRECIS derives 
from the acronym “PRagmatic Explanatory Continuum Indicator Summary”, with the word 
pronounced as “pray-see” and meaning “summary”.  Although Dal-Ré uses examples of sub-
discipline reviews, we discuss also systematic reviews of intervention effectiveness, into 
which PRECIS-2’s measure of design features and usefulness for choosing between 
interventions could be incorporated. This would complement the Cochrane Risk of Bias 
score3, which permits users to consider the quality of trials in their decision.  
 
Dal-Ré proposes that any one of 3 features (a placebo control group, masking/blinding of 
participants or providers, or any RCT conducted only in a single centre) should automatically 
categorize the entire trial and its findings as maximally explanatory, without assessing the 
degree of pragmatism of the nine domains of PRECIS-2. Dal-Ré also challenges the use of the 
main peer reviewed trial report as the main documentary source on which to base 
retrospective assessment of an RCT and raises questions about the potential for bias if the 
design features of a trial appear to have changed between information sources. Finally, he 
proposes that, where information is missing or unclear that domain should be scored as a 
blank. We respond to these constructive suggestions in order. 
 
An RCT with placebo control or blinding cannot support decision making 
We consider these two characteristics together, as placebo control is functionally connected 
with blinding. In combination these eliminate the placebo effect, the effect of subjective 
belief in an intervention on outcome. Even though this effect is generally small4, placebo 
control with blinding has become an RCT design default even when not needed, e.g., in RCTs 
with objective outcomes. Dal-Ré proposes that any RCT that uses a placebo comparator or 
blinds the participants (patients and/or providers) in a trial departs so far from the usual 
care in that setting that the RCT as a whole should automatically be classified as maximally 
explanatory, without further assessment of PRECIS-2 domains. We see this as a question of 
the appropriateness of dichotomization as pragmatic or explanatory for the intentions 
underlying a trial, for the trial as a whole, and for individual design features. 
 
Schwartz and Lellouch describe the intention of the designers for their trial as a dichotomy, 
either predominantly pragmatic or predominantly explanatory; and individual features as 
potentially a mixture of more pragmatic or more explanatory; but they almost always avoid 
dichotomizing any trial as a whole as pragmatic or explanatory. PRECIS-2 authors agree, 
focusing on individual design features, adding the nuance that each feature is on a 
continuum between explanatory and pragmatic, and steering away from assessing the trial 
as a whole.  
 
For Schwartz and Lellouch the starting point for pragmatism is the intention to design a trial 
whose findings are useful for decision-making, followed by selection of design 
characteristics to match that intention. They describe placebo control and blinding as a 
design choice typical of an explanatory rather than a pragmatic intention, but they also 
emphasize a multi-factorial approach to the match between intention and design, in which 
each of several characteristics may align to a greater or lesser extent with the intention of 
the RCT. While we agree that placebo treatment with blinding is seldom part of real-world 
care, there are situations in which a trial could include a placebo control with blinding, while 
still providing information that directly informs a decision.  
 
Consider a two arm, placebo-controlled trial of a new treatment (with unknown risks, or 
expensive), aimed at treating a non-life-threatening condition where the outcomes are 
participant reported and amenable to subjective influence. Or consider a comparative 
effectiveness study in which two or more widely accepted treatments are compared with 
each other, with placebos used to disguise the treatment arm from participants to ensure 
that the choice is based not on subjective belief but on biological activity. Decision makers 
balance benefits, costs and harms when the choice between interventions is close. 
Eliminating patient or provider subjectivity as an explanation for effectiveness by use of 
placebos and blinding might provide information that reassures the decisionmaker that the 
apparent superiority of one intervention is not due to subjectivity alone and is thus worth its 
costs and risks. Trials providing such insights fit Schwartz and Lellouch’s definition of 
pragmatic intention. 
 
Review authors should not therefore prematurely categorize any included trial as 
explanatory simply because they believe a single design feature overrides others. Doing so 
supposes that such trials are never useful (see above), that there is strong empirical 
evidence on the relative weight of each design feature in regard to usefulness for decision 
makers, and that it is valid and useful to dichotomize a trial as a whole. PRECIS-2 authors are 
unaware of such empirical evidence, and we and Schwartz and Lellouch would avoid 
labelling trials in their entirety as dichotomously pragmatic or explanatory (preferring that 
decision makers consider the individual design features in all trials in the review). Every 
included trial should therefore be described without prejudice in a review, so that the 
decisionmakers can assess the usefulness to their own choice of each trial according to its 
similarity to their situation on individual design features (PRECIS-2 domains)  
 
Although we do not agree that placebo comparators and blinding overrides other design 
features, we are persuaded by Dal-Re’s argument that this information should be included 
in PRECIS-2, which currently addresses placebo control and blinding only by urging that a 
trial with pragmatic intentions be designed with a usual care comparator. This does not 
work for retrospective use of PRECIS-2 in reviews. Since we prefer to keep a single version of 
the PRECIS-2 tool that can be used for both design and for retrospective assessment of RCTs 
for reviews,  we propose that’ Dal-Ré’s concern regarding the potential distorting effect of 
placebo control and blinding be addressed by re-introducing comparator choice as a 
separate new 10th domain in a PRECIS-2 update.  
 
In the precursor to PRECIS-25 two overlapping domains addressed the comparator: 
comparator flexibility and comparator provider expertise. We propose a single domain 
where the pragmatic end refers to control groups whose participants’ care replicates the 
mix which constitutes usual care in the setting in which the trial was conducted, while the 
explanatory end describes trials with placebo control groups and blinding of participant and 
intervention providers. An active treatment that is usual care, not necessarily in the trial 
setting, could be scored as highly pragmatic on this domain. Blinding of an unobtrusive 
independent assessor is also a pragmatic design choice. In a trial with multiple arms, or 
multiple controls some of which are placebos, we suggest that the PRECIS-2 tool be used 
once for each head-to-head comparison between arms, rather than just once for each trial6. 
 
A single centre trial cannot contribute to decision making 
Dal-Ré proposes that a trial conducted only in a single centre should automatically be 
characterized as fully explanatory. We see this as a question of external validity- how do we 
apply the results of trials with explanatory and pragmatic features to situations outside of 
the trial itself?  
 
Schwartz and Lellouchs’ seminal insight was that RCTs could have one of two intentions or 
purposes, pragmatic or explanatory, and that most trial designers defaulted unthinkingly to 
the latter7. Pragmatic intentions should lead to design of a trial whose findings directly 
inform decisionmakers in the setting of that trial of the average benefits and harms of the 
interventions, and also directly inform external decisionmakers elsewhere, provided that 
the trial sites are a statistically representative sample of the larger universe for which those 
decision makers are responsible. Beyond these exceptions external decisionmakers need to 
judge for themselves whether their situation is similar enough on major contextual features 
to that of the trial that the same outcomes are likely.  By completing a PRECIS-2 appraisal of 
a trial with pragmatic intentions, external decisionmakers can see that few or no design 
restrictions (on domains such as participant inclusion, flexibility and resources for 
intervention delivery, outcomes and intensity of measurement) were added to complicate 
their judgement. The judgement of similarity and thus applicability is then straightforward, 
although never guaranteed, given unknown or unmeasured differences between the trial 
and their own context. 
 
By contrast, explanatory intentions lead to design of a trial whose findings deepen scientific 
understanding of a hypothesized mechanism of action of an intervention. Because of the 
design restrictions imposed to highlight this mechanism, the situation of an explanatory trial 
is not similar to any real-world setting, and so the trial findings cannot be directly applied 
anywhere, not even in the setting of the trial itself (once the trial is over and usual care 
returns). Instead, application of findings from a trial designed with explanatory features 
must be based on the argument that the mechanism demonstrated to operate in the trial is 
dominant over any contextual differences in participants, delivery, outcome measures or 
other factors in the situation to which its findings are being applied. This judgement of 
applicability must be based upon many counterfactual assumptions and is therefore less 
direct and thus less likely to be reliable than for a trial with more pragmatic features.  
 
We agree that evidence from a trial with pragmatic design choices and multiple centres 
suggests wide applicability of its findings and is reassuring for an external decisionmaker. 
But there will also be decisionmakers for whom the findings of a single centre trial are 
useful, either because they are making decisions for that centre itself post-trial, or because 
they are confident that their own situation is very similar to that single centre. With this 
potential overriding feature, as with placebo and blinding, we feel that prejudging some 
trials in a systematic review as fully explanatory on the basis of a single overriding 
characteristic would eliminate from consideration those that might, aside from their 
number of sites, be pragmatic in intention and in other domains. We also want to point out 
that consideration of the number of sites in a trial is already assessed under Domain 3 in the 
PRECIS-2 tool. 
 
PRECIS-2 cannot be assessed retrospectively using only the main published RCT report 
Dal-Ré points out that the main trial report may often leave out important details and 
argues that this precludes reliable assessment of the items in the PRECIS-2 tool.  We see this 
as an issue of quality control on trial reports.  
 
There is a well-recognized, repeatedly updated, and evidence based template for the main 
trial report: the CONSORT statement, with multiple subtypes for specific kinds of RCTs, 
including those defined by structure, such as cluster randomized or stepped wedge trials, 
and even for specific intentions, such as our CONSORT extension for trials with pragmatic 
intent. Not only are these templates widely accepted by trial researchers, they are required 
by many journals at submission.  This pressure for the published trial report to be highly 
standardized may be improving quality of reporting8.  We expect that with further updates, 
many of the information gaps in published reports of RCTs will shrink. This contrasts with 
trial registration: although required by journals, only a bare minimum of information is 
entered into the registration website, much less than in the final report; and although 
SPIRIT, the trial protocol template is standardized there is no requirement that protocols 
use it.  We agree with Dal-Ré that the trial report is less than perfect but in balancing these 
considerations we propose that retrospective assessments using PRECIS-2 for systematic 
reviews continue to rely primarily on the main published peer reviewed report of each RCT. 
Trial designers could  make the task of reviewers and retrospective assessors easier by using 
the CONSORT extension for Pragmatic trials9 to ensure that all the key information specific 
to RCTs with pragmatic intent is included in their trial report; and, as Dal-Rè has suggested, 
by also reporting their own PRECIS-2 assessment in that report.   
 
Focusing on the published main RCT report avoids the need for dealing with changes to trial 
descriptions that may have arisen between earlier documents (trial registration record, trial 
protocol) and the peer reviewed published final paper. While this may incur some risk of 
using erroneous or falsified information, it is not practical given the length of the usual 
protocol (tens to hundreds of pages) for the researcher conducting a systematic review to 
act as a forensic reader and compare every document describing every trial, even less so for 
decisionmakers including clinicians, health system managers, or policy makers.  Since use of 
these other documents is not mandatory for high quality Cochrane reviews it seems out of 
place to insist on it for the PRECIS-2 assessment. Cochrane reviews already require massive 
effort and if PRECIS-2 is to be integrated into Cochrane systematic reviews, which is our 
hope, we need to take care not to add work without evidence of value.   
 
Dealing with missing information on PRECIS-2 domains 
On occasion, the published RCT report fails to provide enough information to assess 
(retrospectively) the score for one or more domains.  There are a few situations in which a 
domain may be justifiably excluded from a trial and PRECIS-2 recommends it be left blank. If 
one of the domains is irrelevant, e.g. efforts to maintain adherence on the part of the 
patient where the intervention is defined as receipt of a single surgical procedure, it should 
be left blank. Although rare, if a trial is being designed to evaluate an intervention which 
directly aims to change an outcome that is also used to score a domain of the PRECIS-2 tool 
(for example, adherence10) that domain should be left blank. But Dal-Ré has identified a 
contradiction between our recommendation for scoring PRECIS-2 domains with inadequate 
information during design (leave blank and explain reason in table or text), and when 
retrospectively assessing trials in a review (score as a middle value: 3). Dal-Ré points out 
that this latter approach biases the domain score towards 3 and recommends instead that 
missing information from a trial in a review should be treated as it would be in a trial during 
design, and left blank. We agree and will include this in the next update of the PRECIS-2 
tool. The denominator for the total PRECIS-2 score for such a trial should match the number 
of domains for which data is available. There would be fewer blank domains if trial designers 
using PRECIS-2 also used the CONSORT statement for reporting their completed RCT. 
 
Conclusion 
We would like to thank Dal-Ré and others in this community for their longstanding and 
constructive engagement with the ideas of Schwartz and Lellouch. The value of 
randomization to trials was quickly obvious, but it has taken longer for their insight into 
pragmatic and explanatory intentions to be absorbed. We look forward to the realization of 
their vision: “…..(T)he distinction between the two kinds of research, the one aiming to 
extend our field of knowledge, the other aiming at rational decision making, concerns an 
area far broader than that of clinical trial. …….(G)eneralizing the distinction to the broadest 
fields of research cannot but lead to fruitful consequences”11.  
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